Voyager Therapeutics (Nasdaq: VYGR) shares dropped -14.73% to $7.7 in the After-market session on Tuesday after the U.S. Neurocrine Biosciences (Nasdaq: NBIX) has been told by the Food and Drug Administration (FDA) that it has put a clinical hold on the NBIb-1817b clinical trial RESTORE-1 (VY-AADC). It was previously disclosed that sites participating in RESTORE-1 had not been screening, enrolling, or dosing patients due to the ongoing COVID-19 pandemic and more recently, the independent Data Safety Monitoring Board’s request to pause the study in order to collect additional data. The DSMB sought further patient level data from the study and is now preparing to revisit this data at the beginning of 2021. The clinical retention follows the submission of an IND Safety Report by Neurocrine Biosciences pertaining to the observation of MRI anomalies in certain members of the RESTORE-1 trial. At present, the clinical effects of this finding are uncertain and are being assessed.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
RESTORE-1 is a phase 2 clinical trial of the intracerebral AAV-based investigational gene therapy NBIb-1817 (VY-AADC) in progress for Parkinson’s disease treatment. As well as the research investigators and national and local ethics boards, the RESTORE-1 DSMB was told of the therapeutic keeping. In order to define the next steps for the RESTORE-1 clinical trial, Neurocrine Biosciences and Voyager will collaborate closely with the FDA and the DSMB.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Read More
